SCHEMBL21085012

SCHEMBL21085012

O=C(O)CCC1C[CH]CCC1C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.35
CYP2C9 P11712 1/20 0.35
MEN1 O00255 1/20 0.35
NR1I2 O75469 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
THRB P10828 1/20 0.35
TSHR P16473 1/20 0.35
ACHE P22303 1/20 0.35
APEX1 P27695 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
SAE1 Q9UBE0 1/20 0.35
UBA2 Q9UBT2 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TARDBP Q13148 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21085019 0.85 HSD17B10 (0.35) HSD17B10CYP2C9MEN1NR1I2ALDH1A1
SCHEMBL21085017 0.83 GABRR1 (0.32) GABRR1GABRR2
SCHEMBL21085153 0.82 HSD17B10 (0.38) HSD17B10CYP2C9MEN1NR1I2ALDH1A1
SCHEMBL21085149 0.81 SLC6A12 (0.39) MEN1ALDH1A1LMNATSHRBLM
SCHEMBL21085029 0.80 POLB (0.31) POLBGABRR1GABRR2
SCHEMBL21085138 0.79 ALOX5 (0.31) HSD17B10CYP2C9MEN1NR1I2ALDH1A1
SCHEMBL21085088 0.79 GABRR1 (0.34) ALDH1A1GABRR1GABRR2
SCHEMBL21085126 0.78 HSD17B10 (0.35) HSD17B10CYP2C9MEN1NR1I2ALDH1A1
SCHEMBL21085068 0.77 ALOX5 (0.33) ALOX5
SCHEMBL21085064 0.76 HSD17B10 (0.36) HSD17B10CYP2C9MEN1NR1I2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759749-B2 Therapeutic agent for diabetes JCR PHARMACEUTICALS CO., LTD. (JP) 2020-09-01 US disclosed
EP-3508474-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR Pharmaceuticals Co., Ltd. (JP) 2019-07-10 EP disclosed
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR PHARMACEUTICALS CO., LTD. (JP) 2019-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES GPR119, IAPP, DPP4 HSD17B10 1592/4885CYP2C9 4637/4885MEN1 4253/4885
US-10759749-B2 Therapeutic agent for diabetes GPR119, IAPP, DPP4 HSD17B10 1739/4885CYP2C9 3697/4885MEN1 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.